Abstract

The Section is the statistical and data management component of the Center for Cancer Research (CCR). The Section provides statistical leadership and data management consultation for major activities of the Center, and is involved in the design, conduct, monitoring, and statistical analyses of intramural and national multicenter clinical trials of experimental treatments for cancer, and intramural clinical trials for treatment of AIDS. The section provides a broad range of data analysis and consultation services to laboratories performing basic scientific research into the origin and growth mechanisms of cancer and AIDS. Other major collaborative efforts include studies to identify important prognostic and treatment selection factors, evaluate diagnostic procedures, develop improved staging systems, and assist investigators in the design, execution, and analyses of major in vitro drug testing studies. The Section develops and implements new statistical designs and biometric methods related to the development and evaluation of new cancer and AIDS treatments. The Section maintains a unified system for tracking basic information on all patients registered on CCR treatment protocols. Approximately 20% of the Section's activities are HIV-AIDS related.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC007202-23
Application #
7594779
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
23
Fiscal Year
2007
Total Cost
$823,438
Indirect Cost

  Institution

Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Patterson, L Jean; Beal, Jennifer; Demberg, Thorsten et al. (2008) Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. Virology 374:322-37
Gril, Brunilde; Palmieri, Diane; Bronder, Julie L et al. (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092-103
Wilson, Wyndham H; Dunleavy, Kieron; Pittaluga, Stefania et al. (2008) Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26:2717-24
Sissung, Tristan M; Baum, Caitlin E; Deeken, John et al. (2008) ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14:4543-9
Williams, Joy A; Lumsden, Joanne M; Yu, Xiang et al. (2008) Regulation of thymic NKT cell development by the B7-CD28 costimulatory pathway. J Immunol 181:907-17
Madan, Ravi A; Gulley, James L; Schlom, Jeffrey et al. (2008) Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 14:4526-31
Gulley, James L; Arlen, Philip M; Tsang, Kwong-Yok et al. (2008) Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 14:3060-9
Vaccari, Monica; Mattapallil, Joseph; Song, Kaimei et al. (2008) Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J Virol 82:9629-38
Denduluri, Neelima; Yang, Sherry X; Berman, Arlene W et al. (2008) Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther 7:15-20
Azad, Nilofer S; Posadas, Edwin M; Kwitkowski, Virginia E et al. (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709-14

Showing the most recent 10 out of 127 publications